Aurobindo Pharma Q4 PBT rises 32% to Rs1077.51 cr over higher revenue

Revenues from operations for the quarter under review registered 16.4% growth at Rs 6158.43 crore as compared to Rs 5324.47 crore in the year ago period

Indian drug major Aurobindo Pharma Limited reported a 32 per cent jump in profit before tax (PBT) at Rs 1077.51 crore for the quarter ended March 31, 2020 as compared to Rs 816.34 in the corresponding quarter of the previous year on the back of increased revenue fuelled by formulations business growth across geographies.
 

Revenues from operations for the quarter under review registered 16.4 per cent growth at Rs 6158.43 crore as compared to Rs 5324.47 crore in the year ago period. US formulations sales, which contributed nearly 50 per cent of the revenues in this quarter, grew by 20.5